Ridgetech Inc Dossier
|
SectorHealth Care IndustryDrug Retail Beta (adjusted)0.27 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.85Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $3.1M Enterprise Value −$10.2M Shares Outstanding 3.6M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ridgetech Inc. (formerly China Jo-Jo Drugstores Inc.) has undergone a major strategic pivot, divesting its low-margin retail pharmacy operations in February 2025 to focus entirely on online and offline pharmaceutical wholesale distribution. This transition is anchored by its dual-engine growth strategy, combining its offline wholesale platform (Zhejiang Jiuxin Medicine) with its newly acquired online B2B platform (Allright). While the digital expansion offers a path to higher margins and nationwide scale, the company faces severe near-term profitability challenges (gross margin of 3.2% in the trailing twelve months) and significant dilution risks from its $200 million at-the-market offering program. A Hold recommendation is advised until the company demonstrates sustainable margin expansion and successful integration of its supply chain platforms. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.8020% The bear case materializes if the integration between Jiuxin Medicine and Allright stalls, leading to customer churn and operational inefficiencies. Continued pricing pressure in the offline wholesale segment further depresses margins, while aggressive utilization of the $200 million ATM facility heavily dilutes existing shareholders, pushing the stock price back toward Nasdaq non-compliance levels. Base CaseCentral scenario $1.6055% The base case assumes stable revenue generation around $120 million as offline wholesale declines are offset by online platform growth. The company slowly integrates its supply chain systems, but gross margins remain compressed near 3.5% to 4.0% due to intense competition in the Chinese pharmaceutical distribution sector. Dilution from the ATM offering limits EPS upside. Bull CaseUpside scenario $3.5025% The bull case is driven by rapid digital adoption of the Allright platform, successfully expanding its customer base past 300,000 users and achieving a 30% YoY increase in B2B customers. By integrating Jiuxin Medicine's supply chain onto Allright, Ridgetech eliminates distribution layers, improves inventory turnover, and shifts its product mix toward high-margin domestic and international brands, driving gross margins toward high single digits. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |